Centivax has raised $92M across 3 funding rounds.
Centivax raised an oversubscribed $45 million Series A in 2025 led by Steve Jurvetson of Future Ventures, an early backer of Tesla and SpaceX. In 2026 it closed a further $37 million round led by Structure Fund, with participation from Meiji Seika Pharma, Sigmas Group, Kendall Capital Partners, and Patrick and John Collison, funding clinical development of its universal flu vaccine.
3 funding rounds, the latest highlighted.
Centivax was founded in 2017, United States.
A primary round — the company sells new shares to investors it selects. $10M raised, led by NFX, GHIC.
Oversubscribed Series A for universal flu vaccine development. $45M raised, led by Future Ventures.
No filing has been made.
3 dated rounds, newest first.
No. Centivax is a private company; its shares do not trade on a public exchange.
Lead investors for each round are in the funding timeline.
The closest biotechnology - vaccines peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
